Factors determining the maintenance dose of warfarin in Chinese patients

QJM: An International Journal of Medicine

Volumn 89, Issue 2, 1996, Pages 127-135

  Yu, H C M ^a   Chan, T Y K ^a   Critchley, J A J H ^a   Woo, K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; AGE; AGED; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HEART VALVE REPLACEMENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RHEUMATIC HEART DISEASE;

EID: 0030061531     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.2.127     Document Type: Article

References (28)

1. Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51:479-85.
2. Chan TYK, Tsoi WC, Critchley JAJH. The determinants of warfarin requirements in Chinese patients. Pharmacoepidemiol Drug Saf 1992; 1:281-2.
3. Fong PC, Lau CP, Tai YT, Chow WH, Cheung KL. Therapeutic quality control of oral anticoagulation in patients with prosthetic heart valves. J Hong Kong Coll Cardiol 1993; 1:13-18.
4. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol 1979; 15:319-22.
5. Buckley NA, Dawson AH. Drug interactions with warfarin. Med J Aust 1992; 157:479-83.
6. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 28, 1994.
7. O'Malley K, Stevenson IH, Ward CA, Wood AJJ, Crooks J. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol 1977; 4:309-14.
8. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin Pharm Ther 1983; 8:75-7.
9. Redwood M, Taylor C, Jain BJ, Matthews. The association of age and dosage requirement for warfarin. Age Ageing 1991; 20:217-20.
10. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Path 1992; 45:704-6.
11. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ. Racial differences in drug response - altered sensitivity to the clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 1989; 320:565-70.
12. Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995; 75:967-8.
13. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-4.
14. Woo KS, Tse KK, Mak YK, Chung HK, Tse CY. Recombinant tissue plasminogen activator in acute myocardial infarction in the Chinese in Hong Kong. Intern J Cardiol 1992; 36:169-76.
15. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116:901-4.
16. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990; 48:10-17.
17. 1-acid glycoprotein concentration in Chinese and Caucasians. Br J Clin Pharmacol 1991; 31:551-2.
18. Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening complication after dietary modification. Postgrad Med J 1990; 66:855-7.
19. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993; 23:77-82.
20. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4:315-20.
21. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics at steady state. Br J Clin Pharmacol 1979; 8:243-7.
22. Bradbury H, Burns E, Stanners A, Travers AF, McAleer SD, Chrystyn H. The clearance of warfarin and its enantiomers in the elderly. Br J Clin Pharmacol 1992; 34:154-5P.
23. Kamali F, Edwards C, Cope LH, Wynne H. The influence of age, liver volume and plasma enantiomer concentrations upon warfarin dose requirements. Br J Clin Pharmacol 1995; 39:102P.
24. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remedial lesions. Am J Med 1989; 87:153-9.
25. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42:759-64.
26. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of out-patient therapy. Am J Med 1989; 87:144-52.
27. Chan TYK, Chan JCN, Tomlinson B, Critchley JAJH. Adverse reactions to drugs as a cause of admissions to a general teaching hospital in Hong Kong. Drug Saf 1992; 7:144-52.
28. Chan TYK, Critchley JAJH, Chan JCN, Tomlinson B, Chan MTV. Disease profiles in Chinese in Hong Kong: an analysis of the primary diagnoses in 561 acute hospital medical admissions. Southeast Asian J Trop Med Public Health 1993; 24:766-8.